Nutex Health Has A Healthy Pulse And Shows Strong Signs Of Life For Further Gains
Nutex Health is rated Buy, with a DCF-based price target of $199.31, offering 19.8% upside from $166.40. NUTX's revenue surged from $247.6M in FY2023 to $880.0M TTM ended March 31, 2026, driven by effective use of the No Surprises Act's IDR process. Liquidity and leverage metrics have improved, with debt-to-equity falling below 1.0 and the current ratio at 3.1 in the TTM period.
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Nutex Health: The $387 Million Receivables Problem And The Legislative Silver Bullet
Nutex Health is rated a buy, driven by the potential passage of the No Surprises Enforcement Act. NUTX's $387 million in receivables could rapidly convert to cash if the bill passes, eliminating a key valuation overhang. The company trades at 5.2x P/E despite 49% projected 2026 revenue growth and a 27% TTM operating margin, reflecting market skepticism over payment collections.
Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript
Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript
Nutex Health: Fairly Valued After Pullback, But Wait For A More Ideal Entry Point (Rating Upgrade)
Nutex Health Inc. recently posted Q2 and Q3 results, showing strong revenue growth and operating cash flow. NUTX's accounts receivable balance continues to rise, raising questions about the collectability of revenue booked under the No Surprises Act. NUTX's valuation metrics compare very favorably to its peers across the board.
Nutex Health Inc. (NUTX) Q2 2025 Earnings Call Transcript
Nutex Health Inc. (NASDAQ:NUTX ) Q2 2025 Earnings Conference Call August 25, 2025 10:30 AM ET Company Participants Jon C. Bates - Chief Financial Officer Michael Chang - Chief Medical Officer Thomas T.
Nutex Health's Quiet Buy-The-Dip Setup After A Blowout Quarter
Nutex Health is disrupting ER care with micro-hospitals, delivering high-margin, profitable growth, and winning 80%+ of arbitration cases against insurers. Q2 results were a blowout: revenue up 221% YoY, gross margin at 51%, and operating cash flow surging, confirming the business model's strength. Despite a 192% YTD stock rally, Nutex trades at just 0.7x forward sales and 1.5x EV/EBITDA, making it attractively valued versus peers.
Nutex Health: At An Inflection Point
Nutex Health's financial turnaround is driven by IDR wins, robust revenue growth, and a superior urban microhospital model with industry-leading profitability. Shares are deeply undervalued at 2.1x EV/EBITDA and >30% FCF yield, with significant upside as the market underappreciates Nutex's earnings power and cash flow. Management's heavy insider ownership and consistent share purchases signal long-term commitment and confidence in the business model's sustainability.
Nutex Health: Justified Dilution Given Explosive Growth In Free Cash Flow
Nutex Health delivered a blowout Q1 2025, with $51M in free cash flow and 214% y/y revenue growth, driven by arbitration wins. A frank discussion of its equity dilution. The company's growth is impressive but erratic, with limited visibility and heavy reliance on non-recurring arbitration revenue.
Nutex Health Leverages Arbitration To Unlock Hidden Value
Nutex Health is a speculative buy, exploiting a unique arbitrage model under the No Surprises Act for strong revenue and profit growth. The micro-hospital strategy, physician ownership, and focus on efficiency drive staff stability and operational expansion, supporting sustainable volume growth. Financials are robust: Q1 saw a 213% sales jump, a 56% gross margin, strong cash flow, and a healthy balance sheet with modest debt.
Nutex Health Inc.: High-Growth Healthcare Innovator With Strong Momentum
NUTX is transforming from a turnaround story to a high-growth, high-risk play, driven by explosive revenue and profitability from its micro-hospital model. The company's financials show triple-digit revenue growth, margin expansion, and strong operating leverage, with positive analyst sentiment and technical momentum. Key risks include heavy reliance on arbitration revenue, significant lease liabilities, and regulatory uncertainty, making this a volatile but compelling opportunity.
